Regression of Fatty Heart by Valsartan Therapy

NCT00745953 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Conditions

Metabolic Syndrome
Lipotoxicity

Interventions

DRUG: Valsartan
DRUG: Hydrochlorothiazide

Sponsor

University of Texas Southwestern Medical Center

Collaborators

[object Object]